Introduction
============

Retinitis pigmentosa (RP) is a progressive retinal degeneration characterized by night blindness and restriction of peripheral vision. Later in the course of the disease, central and color vision can be lost. Many patients experience the first signs of RP between 20 and 40 years but there is much phenotypic variability from age of onset and speed of deterioration to severity of visual impairment ([@B18]).

Retinitis pigmentosa, whilst classified as a rare disease, is the most common cause of inherited blindness worldwide. It affects between 1:3500 and 1:2000 people ([@B14]; [@B39]), and can be inherited in an autosomal dominant (adRP), autosomal recessive (arRP), or X-linked (xlRP) manner. It may occur in isolation (non-syndromic RP) ([@B45]), or with other features (syndromic RP) as in Bardet--Biedl syndrome, Joubert syndrome and Usher syndrome ([@B32]).

The condition is extremely heterogeneous, with 64 genes identified as causes of non-syndromic RP, and more than 50 genes associated with syndromic RP (RetNet ^[1](#fn01){ref-type="fn"}^). Even with current genetic knowledge, diagnostic detection rate in adRP cohorts remains between 40% ([@B32]) and 66% ([@B55]), suggesting that many disease genes remain to be identified, and many mutations within known genes require characterization to ascribe pathogenic status. Detection rates are as low as 14% in cohorts of simplex cases (single affected individuals) and multiplex cases (several affected individuals in one family but unclear pattern of inheritance) ([@B20]). Such cases account for up to 50% of RP cases, so this presents a significant challenge to diagnosis ([@B16]; [@B17]; [@B34]).

The second most common genetic cause of adRP is *PRPF31*, accounting for 6% of United States cases ([@B41]) 8% of Spanish cases ([@B30]), 8% of French Canadian cases ([@B9]), 8% of French cases ([@B3]), 8.9% of cases in North America ([@B10]), 11.1% in small Chinese cohort ([@B27]), 10% in a larger Chinese cohort ([@B53]) and 10.5% of Belgian cases ([@B44]). However, this is likely to be an underestimate due to variable penetrance of this form of RP, complicating attempts to co-segregate the variant with clinical disease, making genetic diagnosis difficult.

Whilst the majority of reported variants in *PRPF31* are indels, splice site variants and nonsense variants, large-scale deletions or copy number variations ([@B30]), which are easily ascribed pathogenic status, at least eleven missense variants in *PRPF31* have been reported in the literature ([Table 1](#T1){ref-type="table"}). Missense variants are more difficult to characterize functionally than nonsense or splicing mutations ([@B8]) and it is likely that there are false negative diagnoses in patients carrying missense mutations due to lack of confidence in prediction of pathogenicity of such variants. This is reflected in the enrichment of *PRPF31* missense variants labeled 'uncertain significance' in ClinVar, a public repository for clinically relevant genetic variants ([@B24], [@B23]). Furthermore, work has shown that some variants annotated as missense *PRPF31* variants may in fact be affecting splicing of *PRPF31*, introducing premature stop codons leading to nonsense mediated decay (NMD), a common disease mechanism in RP11 ([@B35]). One example is c.319C \> G, which, whilst originally annotated as p.Leu107Val, actually affects splicing rather than an amino acid substitution ([@B35]). The presence of exonic splice enhancers is often overlooked by genetics researchers.

###### 

Summary of published missense mutations in *PRPF31*.

  cDNA variant   protein variant   Found in family or singleton?       Original reference(s)
  -------------- ----------------- ----------------------------------- ------------------------
  c.413C \> A    Thr138Lys         Large family                        [@B48]
  c.581C \> A    Ala194Glu         Single affected individual (SP42)   [@B46]
  c.590T \> C    Leu197Pro         Large generation                    [@B7]
  c.646G \> C    Ala216Pro         Huge family (AD29)                  [@B46]
  c.781G \> C    Gly261Arg         Single affected individual          [@B52]
  c.862C \> T    Arg288Trp         Single affected individual          [@B9]
  c.871G \> C    Ala291Pro         Single affected individual          [@B40]
  c.895T \> C    Cys299Arg         3 independent families              [@B40]; [@B53]; [@B30]
  c.896G \> A    Cys299Tyr         Large family                        [@B6]
  c.1222C \> T   Arg408Trp         Single affected individual          [@B52]
  c.1373A \> T   Gln458Leu         Single affected individual          [@B52]
                                                                       

PRPF31 is a component of the spliceosome, the huge macromolecular ribonucleoprotein (RNP) complex which catalyzes the splicing of pre-messenger RNAs (pre-mRNAs) to remove introns and produce mature mRNAs ([@B51]). The spliceosome is composed of 5 small nuclear RNAs (snRNAs), U1--U5, and many proteins including pre-mRNA splicing factors PRPF3, PRPF4, PRPF6, PRPF8, and SNRNP200, all of which are also genetic causes of RP ([@B37]). It is unclear whether variants in these proteins have an effect on splicing of specific retinal transcripts ([@B11]; [@B54]; [@B33]; [@B50]). Some papers have failed to find any evidence for a generalized RNA splicing defects ([@B36]). Pre-mRNA splicing factors may have additional roles beyond splicing in the nucleus, after a study recently found that PRPF6, PRPF8, and PRPF31 are all localized to the base of the retinal photoreceptor connecting cilium and are essential for ciliogenesis, suggesting that this form of RP is a ciliopathy ([@B49]). Missense variants in these proteins are, collectively, a common cause of adRP. This presents significant challenges in providing accurate diagnosis for patients with missense variants in these genes. Developing tools to provide accurate genetic diagnoses in these cases is a significant clinical priority.

The most commonly used *in silico* predictors of pathogenicity of missense variants, PolyPhen2 ([@B2]) and CADD ([@B22]), which use combined sequence conservation, structural and machine learning techniques only have around 15--20% success rate in predicting truly pathogenic variants ([@B31]). Use of simple tools has around the same success rate ([@B13]), and use of several tools in combination increases reliability ([@B15]). Insight from structural biologists and molecular cell biologists is essential to make accurate predictions.

In this study we take advantage of the recently elucidated structure of the in-tact spliceosome to model the effect of a novel variant in *PRPF31*, found in a patient attending the genetics eye clinic at Bristol Eye Hospital. We combine this *in silico* analysis with *in vitro* studies to characterize this novel variant. We show that analysis of protein complexes *in silico* can complement clinical and laboratory studies in predicting pathogenicity of novel genetic variants.

Materials and Methods {#s1}
=====================

Genetic Testing
---------------

The study was conducted in accordance with the Declaration of Helsinki. Informed consent for diagnostic testing was obtained from the proband in clinic. Genomic DNA was extracted from a peripheral blood sample by Bristol Genetics Laboratory and tested against the retinal dystrophy panel of 176 genes in the NHS accredited Genomic Diagnostics Laboratory at Manchester Centre for Genomic Medicine, United Kingdom.

Splicing Analysis
-----------------

We used Human Splicing Finder ([@B12]) to identify and predict the effect of variants on splicing motifs, including the acceptor and donor splice sites, branch point and auxiliary sequences known to enhance or repress splicing. This program uses 12 different algorithms to make a comprehensive prediction of the effect of variants on splicing.

3D Structural Protein Analysis
------------------------------

PyMol (Schrodinger Ltd.) program was used to characterize the effect of missense variants in human *PRPF31* protein. Missense variants were modeled on PRPF31 in the pre-catalytic spliceosome primed for activation (PDB file 5O9Z) ([@B5]).

Variant Construct Cloning
-------------------------

Full-length, sequence-validated *PRPF31* ORF clone with C-terminal myc tag was obtained from OriGene. c.341T \> A or c.581C \> A variant was introduced using NEB Q5 site-directed mutagenesis kit. The entire wild-type and mutant clone sequence was verified by Sanger sequencing (Source Bioscience).

Cell Culture
------------

HEK293 cells and 661W cells were cultured in DMEM high glucose + 10% FCS at 37°C, 5% CO~2~, and split at a ratio of 1:8 once per week. hTERT-RPE1 cells (ATCC CRL-4000) were cultured in DMEM/F12 (50:50 mix) + 10% FCS at 37°C, 5% CO~2~, and split at a ratio of 1:8 once per week.

Cell Transfection
-----------------

The construct was transfected into HEK293 cells using PEI, and into hTERT-RPE1 and 661W cells using the Lonza Nucleofector.

Inhibition of Protein Translation
---------------------------------

Cells were grown for 72 h, and treated with 30 μg/ml cycloheximide in DMSO. Untreated cells were treated with the equivalent volume of DMSO.

Protein Extraction
------------------

Total protein was extracted from cells using 1% NP40 lysis buffer and scraping. Insoluble material was pelleted by centrifugation at 10,000 ×*g*. Cell fractionation was carried out by scraping cells into fractionation buffer containing 1 mM DTT, and passed through a syringe 10 times. Nuclei were pelleted at 720 ×*g* for 5 min and separated from the cytoplasmic supernatant. Insoluble cytoplasmic material was pelleted using centrifugation at 10,000 ×*g* for 5 min. Nuclei were washed, and lysed with 0.1% SDS and sonication. Insoluble nuclear material was pelleted using centrifugation at 10,000 ×*g* for 5 min.

SDS-PAGE and Western Blotting
-----------------------------

20 μg of total protein per sample with 2 × SDS loading buffer was loaded onto pre-cast 4--12% Bis-Tris gels (Life Technologies) alongside Spectra Multicolor Broad range Protein ladder (Thermo Fisher). Samples were separated by electrophoresis. Protein was transferred to PVDF membrane. Membranes were incubated with blocking solution \[5% (w/v) non-fat milk/PBS\], and incubated with primary antibody overnight at 4°C. After washing, membranes were incubated with secondary antibody for 1 h at room temperature and exposed using 680 nm and/or 780 nm laser, or incubated with SuperSignal West Femto reagent (Pierce) and exposed using Chemiluminescence settings on Li-Cor Odyssey imaging system (Li-Cor).

Primary Antibodies for WB
-------------------------

Mouse anti β-actin clone AC-15. 1:4000. Sigma-Aldrich A1978.

Goat anti-PRPF31 primary antibody 1:1000 (Abnova).

Mouse anti-c myc 1:5000 (Sigma).

Mouse anti PCNA-HRP conjugated 1:1000 (Bio-Rad).

Secondary Antibodies for WB
---------------------------

Donkey anti mouse 680 1:20,000 (Li-Cor).

Donkey anti goat 800 1:20,000 (Li-Cor).

Immunocytochemistry
-------------------

Cells were fixed 24, 48, and 72 h after nucleofection. Cells were fixed in ice-cold methanol at -20°C for 5 min, immediately washed with PBS, and incubated with blocking solution (1% w/v non-fat milk powder/PBS). Coverslips were incubated with primary antibodies at 4°C overnight and with secondary antibodies and DAPI for 1 h at room temperature. Cells were mounted onto slides with Mowiol.

Primary Antibodies for IF
-------------------------

Goat anti-PRPF31 primary antibody 1:200 (Abnova).

Mouse anti-c myc 1:1000 (Sigma).

Rabbit anti-caspase 3 1:500 (Abcam).

Secondary Antibodies for IF
---------------------------

Donkey anti mouse IgG Alexa Fluor 488 1:500.

Donkey anti goat IgG Alexa Fluor 633 1:500.

Goat anti rabbit IgG Alexa Fluor 488 1:1000.

Goat anti mouse IgG Alexa Fluor 568 1:1000.

Confocal Imaging
----------------

Confocal images were obtained at the Centre for Research in Biosciences Imaging Facility at UWE Bristol, using a HC PL APO 63×/1.40 oil objective CS2 lens on a Leica DMi8 inverted epifluorescence microscope, attached to a Leica SP8 AOBS laser scanning confocal microscope, or in the Bioimaging Unit of University of Southampton, using a HC PL APO 63×/1.30 glycerol objective lens on a Leica DMi8 inverted epifluorescence microscope, attached to a Leica SP5 laser scanning confocal microscope. For publication, images were captured using LASX or LAS Af software, assembled in Adobe Photoshop, and figures prepared using Adobe Illustrator. For image analysis, images were captured using LASX software, assembled in Adobe Photoshop and randomized for analysis by an independent researcher blinded to the identity of samples.

Results
=======

Clinical Description of c.341T \> A p.Ile114Asn Patient
-------------------------------------------------------

A 39 years old female presented to the Genetic Eye clinic at Bristol Eye Hospital in 2013 complaining of some difficulty with dark adaptation, driving at night and a reduction in her field of vision (having to turn her head to see her children). Her general health was otherwise good. Over a 4 years period her best corrected visual acuity remained good at 6/6-3 right eye and 6/7.5 left eye (Snellen equivalent using a LogMar chart) whilst her peripheral vision deteriorated from an isolated mid-peripheral scotoma to tunnel vision by 2017 ([Figure 1A](#F1){ref-type="fig"}). Fundoscopy showed widespread bilateral bone spicule pigmentation, attenuated retinal vessels and pale optic nerves typical of RP ([Figure 1B](#F1){ref-type="fig"}). There was no evidence of lens opacities or macula oedema in either eye.

![Clinical characteristics of patient at visit in 2017. **(A)** Goldmann visual field images show bilateral tunnel vision with a small island of peripheral vision in the right eye. Both the I4e (turquoise line) and III4e (purple line) targets were used to plot the visual fields. Using the commonly used III4e target in both eyes, the visual fields extend from 10 degrees temporally to 40 degrees nasally along the horizontal and 15 degrees above and below fixation in the right eye with a peripheral island of vision in the inferotemporal quadrant. The peripheral fields in the left eye are constricted to the central 15 degrees. **(B)** Red-free fundus photographs show extensive bilateral retinal pigment disruption. Arrowheads point to areas of pigment defects in the periphery of the fundus for both eyes. Areas of defects are larger and more confluent in the nasal compared to temporal periphery.](fgene-10-00248-g001){#F1}

Variant Analysis of c.341T \> A p.Ile114Asn
-------------------------------------------

The patient described other family members having similar symptoms and losing their sight at a relatively young age ([Figure 2A](#F2){ref-type="fig"}). A heterozygous *PRPF31* change, c.341T \> A p.Ile114Asn was identified in the patient and her asymptomatic father, which was confirmed by bidirectional Sanger sequencing. All affected members of the family were on the father's side. We were not able to contact any other affected relatives for testing. Pathogenic variants in *PRPF31* are associated with a form of RP which shows incomplete penetrance, consistent with the pattern of inheritance seen in this family. The PRPF31 c.341T \> A p.Ile114Asn variant is not present in the heterozygous or homozygous state in any individuals within the gnomAD database, nor are any other variants affecting Ile114, suggesting that this is a highly conserved residue. Analysis by PolyPhen2 suggested this change was probably damaging, with a score of 0.963 ([Figure 2B](#F2){ref-type="fig"}) and SIFT concurred with this prediction with a score of 0.0. Comparative genomic alignment shows the residue to be conserved from humans to amphibia, within a highly conserved region, conserved across diverse metazoa including sponges ([Figure 2B](#F2){ref-type="fig"}). The Grantham score (Grantham, 1974) is 149, where 0--50 is conservative, 51--100 is moderately conservative, 101--150 is moderately radical and \>151 is radical ([@B26]).

![Pedigree, PolyPhen2 and conservation analysis of *PRPF31* c.341T \> A Ile114Asn variant. **(A)** Family pedigree. Affected individuals in generation II had visual symptoms suggestive of retinitis pigmentosa and appear on both sides of the paternal grandparents of the proband. Arrow = proband. Asterisk = father of proband, also found to possess heterozygous *PRPF31* c.341T \> A Ile114Asn variant. **(B)** PolyPhen2 score predicts this variant is probably damaging with a score of 0.963 (top), alignment of PRPF31 sequence showing conservation of Ile114 and surrounding amino acids (bottom). Ile114 identity is conserved across tetrapods, from human to *Xenopus tropicalis*, and non-polar hydrophobic similarity is conserved from yeast to human, with variations in highly derived insects (*Drosophila melanogaster*) and fish (*Fugu*).](fgene-10-00248-g002){#F2}

Splicing Analysis of Genetic Single Nucleotide Variants in *PRPF31*
-------------------------------------------------------------------

We undertook *in silico* splicing analysis of our novel variant of interest c.341T \> A p. Ile114Asn and found that it was not predicted to affect splicing. We also studied the nine published variants in *PRPF31* annotated as missense, and interestingly, five were predicted to potentially alter splicing, and one \[c.1373A \> T, p. Gln458Leu ([@B52])\] was predicted to be highly likely to affect splicing ([Table 2](#T2){ref-type="table"}). This suggests that either this splice predictor should be used with caution, or that p.Gln458Leu may be mis-annotated as a missense variant, when it actually affects splicing. We suggest that this variant should be a priority for further functional characterization *in vitro*.

###### 

Mutations in PRPF31 annotated as missense, and their predicted impact on splicing.

  cDNA variant   Protein variant   Predicted effect on splicing (Human Splicing Finder)   Notes                                                                    Summary - effect on splicing?   Estimate of pathogenicity
  -------------- ----------------- ------------------------------------------------------ ------------------------------------------------------------------------ ------------------------------- ---------------------------
  c.413C \> A    Thr138Lys         Potential alteration of splicing                                                                                                Maybe                           Pathogenic
  c.581C \> A    Ala194Glu         Potential alteration of splicing                       Functional characterization shows functional effect of missense change   No                              Pathogenic
  c.590T \> C    Leu197Pro         Potential alteration of splicing                       Functional characterization shows functional effect of missense change   No                              Pathogenic
  c.646G \> C    Ala216Pro         Potential alteration of splicing                       Functional characterization shows functional effect of missense change   No                              Pathogenic
  c.781G \> C    Gly261Arg         No impact on splicing                                                                                                           No                              Pathogenic
  c.862C \> T    Arg288Trp         Potential alteration of splicing                                                                                                Maybe                           Pathogenic
  c.871G \> C    Ala291Pro         No impact on splicing                                                                                                           No                              Pathogenic
  c.895T \> C    Cys299Arg         No impact on splicing                                                                                                           No                              Pathogenic
  c.896G \> A    Cys299Tyr         Potential alteration of splicing                                                                                                Maybe                           Pathogenic
  c.1222C \> T   Arg408Trp         Potential alteration of splicing                                                                                                No                              Pathogenic
  c.1373A \> T   Gln458Leu         Most probably affecting splicing                                                                                                Yes                             Pathogenic
                                                                                                                                                                                                   

All published missense mutations in PRPF31, and their predicted impact on splicing, according to Human Splicing Finder

.

3D Structural Analysis of Missense Variants in PRPF31
-----------------------------------------------------

We mapped all published missense variants onto the PRPF31 protein structure in the pre-catalytic spliceosome. For simplicity, we only show PRPF31 in complex with U4 snRNA and 15.5K (SNU13) protein ([Figure 3](#F3){ref-type="fig"}) and (in complex with PRPF6 in [Supplementary Figure S1](#SM1){ref-type="supplementary-material"}; in complex with PRPF8 in [Supplementary Figure S2](#SM2){ref-type="supplementary-material"}). This showed that variants are located throughout the protein, but concentrated in several key domains. Three variants (Arg288Trp, Ala291Pro, and Cys299Arg), are located in α-helix 12 of the protein, in the Nop domain which interacts with RNA and the 15.5K (SNU13) protein. Three variants are in α-helix 6 of the coiled-coil domain (Ala194Glu, Leu197Pro, and Ala216Pro) and one variant is in α-helix 3 of the protein in the coiled-coil tip (Thr138Lys). Gly261Arg is within the flexible loop between the Nop and coiled-coil domains and Arg408Trp alone is in the C-terminal domain.

![3D cartoon representation of PRPF31, including published missense mutations. Cartoon representation of alpha helical structure of PRPF31 (gray) and 15.5K/SNU13 (pink) with U4 snRNA (orange backbone), with published missense mutations mapped onto the physical structure, with wild-type amino acid structure in green, and mutant amino acid structure overlaid in red.](fgene-10-00248-g003){#F3}

Analysis of interactions within 4 Å of each amino acid show that in most cases (Thr138Lys, Ala194Glu, Gly261Arg, Arg288Trp, Ala291Pro, and Cys299Arg), these substitutions are predicted to affect hydrogen (H) bonding in PRPF31. H bonds with donor-acceptor distances of 2.2--2.5 Å are strong and mostly covalent; 2.5--3.2 Å are moderate mostly electrostatic and 3.2--4 are weak electrostatic interactions and can be predicted to be affecting protein folding and solubility ([@B19]). In the case of Arg408Trp, the substitution does not affect H bonding within PRPF31, but does introduce a new interaction with neighboring PRPF6 ([Figure 4A](#F4){ref-type="fig"} and [Supplementary Figures S1](#SM1){ref-type="supplementary-material"}, [S2](#SM2){ref-type="supplementary-material"}). Gly261Arg also introduces a new interaction with neighboring PRPF8 ([Figure 4B](#F4){ref-type="fig"} and [Supplementary Figure S2](#SM2){ref-type="supplementary-material"}). Of the three small substitutions which do not affect H bonding, we discovered that in all cases the variant amino acid was proline, which introduces a new kink in the amino acid chain. Each of these substitutions also resulted in the loss of a polar contact ([Figure 4C--E](#F4){ref-type="fig"}).

![3D cartoon representation of regions of PRPF31 with published missense mutations and their interactions with other molecules within 4 Å, and their polar contacts. Cartoon representation of alpha helical structure of regions of PRPF31 (gray), with published missense mutations **(A)** Arg408Trp showing how this affects interaction with PRPF6 (blue) and **(B)** Gly261Arg showing how this affects interaction with PRPF8 (orange). Red asterisks are used to label where missense mutations introduce new H bonding. Cartoon representation of alpha helical structure of regions of PRPF31 (gray), with published missense mutations **(C)** Leu197, **(D)** Ala216Pro, and **(E)** Ala291Pro showing effect of these missense mutation on loss of polar contacts within PRPF31. Wild-type amino acid structure is shown in green, and mutant amino acid structure overlaid in red. Green asterisk shows polar contacts which are lost upon missense mutation.](fgene-10-00248-g004){#F4}

We next mapped the variant found in our patient attending the genetics eye clinic at Bristol Eye Hospital; Ile114Asn ([Figure 5A](#F5){ref-type="fig"}). Ile114Asn is in the coiled-coil domain of the protein, in close proximity to published pathogenic variants Thr138Lys and Ala194Glu ([Figure 5B](#F5){ref-type="fig"}). The substitution introduces new H bonds between this residue and Ala190 of an adjacent α-helix, and is predicted to affect protein folding and solubility, and be pathogenic ([Figure 5C](#F5){ref-type="fig"}).

![3D cartoon representation of PRPF31 and variant Ile114Asn. **(A)** Cartoon representation of alpha helical structure of PRPF31 (gray) and 15.5K/SNU13 (pink) with U4 snRNA (orange backbone), with published missense mutations mapped onto the physical structure, with wild-type amino acid structure in green, and mutant amino acid structure overlaid in red. Ile114Asn (black arrow) is mapped onto the structure with wild-type amino acid structure in green, and mutant amino acid structure overlaid in blue. **(B)** Cartoon representation of alpha helical structure of subregion of PRPF31 (gray), with Ile114Asn, showing proximity to Thr138 and Ala194, both of which are published sites of mutation in RP patients. **(C)** Ile114Asn mapped onto the physical structure of PRPF31 with wild-type amino acid structure in green, and mutant amino acid structure overlaid in blue, and interactions within 4 Å, predicted to affect H bonding within PRPF31. Green regions of the alpha helix denote normal H bonding by Ile114, blue regions of the alpha helix denote novel H bonds of Asn114. Blue asterisks are used to label where missense mutation introduces new H bonding.](fgene-10-00248-g005){#F5}

The effect of missense variants is summarized in [Table 3](#T3){ref-type="table"}.

###### 

Summary of *in silico* analysis of missense mutations in PRPF31.

  cDNA mutation   Protein mutation   Original reference(s)    Predicted effect on splicing (Human Splicing Finder)   Location in protein                SIFT score                                                   PolyPhen score              Grantham score   Affects H bonding within PRPF31?   Affects H bonding with other proteins?   Affects polar contacts in PRPF31?
  --------------- ------------------ ------------------------ ------------------------------------------------------ ---------------------------------- ------------------------------------------------------------ --------------------------- ---------------- ---------------------------------- ---------------------------------------- -----------------------------------
  c.319C \> G     Leu107Val          [@B35]                   IMPACTS SPLICING - confirmed *in vitro*                Coiled coil domain alpha helix 1   0.04 (affects protein function)                              0.074 (benign)              32               --                                 --                                       --
  c.341T \> A     Ile114Asn          This paper               No impact on splicing                                  Coiled coil domain alpha helix 1   0.00 (affects protein function)                              0.963                       149              Y                                  N                                        N
  c.413C \> A     Thr138Lys          [@B48]                   Potential alteration of splicing                       Coiled coil tip alpha helix 3      0.05 (tolerated)                                             1                           78               Y                                  N                                        N
  c.581C \> A     Ala194Glu          [@B46]                   Potential alteration of splicing                       Coiled coil domain alpha helix 6   0.02 (affects protein function)                              1                           91               Y                                  N                                        N
  c.590T \> C     Leu197Pro          [@B7]                    Potential alteration of splicing                       Coiled coil domain alpha helix 6   0.00 (affects protein function)                              1                           98               N                                  N                                        Y
  c.646G \> C     Ala216Pro          [@B46]                   Potential alteration of splicing                       Coiled coil domain alpha helix 6   0.00 (affects protein function)                              1                           27               N                                  N                                        Y
  c.781G \> C     Gly261Arg          [@B52]                   No impact on splicing                                  Flexible loop                      0.01 (affects protein function)                              0.999                       125              Y                                  Y (PRPF8)                                N
  c.862C \> T     Arg288Trp          [@B9]                    Potential alteration of splicing                       Nop domain alpha helix 12          0.00 (affects protein function)                              1                           101              Y                                  N                                        N
  c.871G \> C     Ala291Pro          [@B40]                   No impact on splicing                                  Nop domain alpha helix 12          0.09 (tolerated)                                             1                           27               Y                                  N                                        Y
  c.895T \> C     Cys299Arg          [@B40]; [@B53]; [@B30]   No impact on splicing                                  Nop domain alpha helix 12          0.00 (affects protein function)                              1                           180              Y                                  N                                        N
  c.896G \> A     Cys299Tyr          [@B6]                    Potential alteration of splicing                       Nop domain alpha helix 12          0.00 (affects protein function)                              0.997                       194              Y                                  N                                        N
  c.1222C \> T    Arg408Trp          [@B52]                   Potential alteration of splicing                       C-terminal domain                  0.00 (affects protein function). Low confidence prediction   1                           101              N                                  Y (PRPF6)                                N
  c.1373A \> T    Gln458Leu          [@B52]                   Most probably affecting splicing                       C-terminal domain                  0.00 (affects protein function). Low confidence prediction   0.931 (possibly damaging)   113              --                                 --                                       --
                                                                                                                                                                                                                                                                                                                                              

To test the accuracy of our predictions, we took on c.341T \> A p.Ile114Asn for further *in vitro* characterization.

*In vitro* Analysis of c.341T \> A p.Ile114Asn Variant
------------------------------------------------------

To investigate whether c.341T \> A p.Ile114Asn caused mislocalization of the protein, we transfected hTERT-RPE1 cells, an immortalized cell line derived from human retinal pigment epithelium, with plasmids expressing either wild-type (WT) PRPF31 or PRPF31 341T \> A, both tagged with c-myc epitope tag. We used the Lonza nucleofector to ensure high transfection efficiency. We assayed the cells after 24, 48, and 72 h by immunofluorescence confocal microscopy using an anti-cmyc antibody. At 24 h we saw mid- to high-level expression of the WT protein exclusively in the nucleus of, on average, 52.5% of cells ([Figure 6A](#F6){ref-type="fig"}). This gradually reduced at 48 h (44.0% of cells), and 72 h (34.4%) ([Figure 6A](#F6){ref-type="fig"}). We did not observe the same pattern in cells expressing the mutant protein. In these cells, only 9.11% of cells showed nuclear c-myc staining at 24 h, and it was very intense, and also observed in the cytoplasm ([Figure 6A](#F6){ref-type="fig"}). This was maintained at 48 h (11.9%), but dropped to 7.5% of cells at 72 h ([Figure 6A](#F6){ref-type="fig"}). The difference in c-myc staining, in terms of % of cells with nuclear staining and % of cells with cytoplasmic staining, was statistically significant at all time points with the exception of cytoplasmic staining at 48 h (*t*-test, *p* \< 0.05, *n* = 4 independent biological replicates) ([Figure 6B](#F6){ref-type="fig"}). At each time point, many cells transfected with mutant PRPF31 showed abnormal nuclear morphology, with some micronuclei present ([Figure 6C](#F6){ref-type="fig"}). There were statistically significantly more abnormal nuclei and micronuclei in the mutant cells compared to WT at 48 and 72 h (paired *t*-test, *p* \< 0.05, *n* = 4 independent biological replicates) ([Figure 6D](#F6){ref-type="fig"}). To confirm these findings, we compared these findings to cells transfected with PRPF31 c.581C \> A p.Ala194Glu, and observed a similar pattern of staining and nuclear changes, although we were not able to calculate the statistical significance of these observations (*n* = 2) ([Supplementary Figure S3](#SM3){ref-type="supplementary-material"}). We also repeated these experiments in the 661W cell line, which is derived from mouse cone photoreceptor cells ([@B42]). Although we achieved lower transfection efficiency, we observed the same pattern of c-myc staining as we saw in the hTERT-RPE1 experiments. At 24 h we saw mid- to high-level expression of the WT protein exclusively in the nucleus of around 16.2% of cells ([Figure 7A](#F7){ref-type="fig"}). We did not observe the same pattern in cells expressing the mutant protein. In these cells, at 24 h, only around 7.9% of cells showed c-myc staining in the nucleus, and it was very intense and also throughout the cytoplasm ([Figure 7A](#F7){ref-type="fig"}). The difference in c-myc staining, in terms of % of cells with nuclear staining, was statistically significant at all time points (*t*-test, *p* \< 0.05, *n* = 3 independent biological replicates) ([Figure 7B](#F7){ref-type="fig"}). Again, we saw more abnormal nuclei and micronuclei in cells transfected with mutant PRPF31 compared to WT after 48 and 72 h ([Figure 7C](#F7){ref-type="fig"}). The number of micronuclei was significantly higher in mutant cells at 48 and 72 h (*t*-test, *p* \< 0.05, *n* = 3 independent biological replicates) ([Figure 7D](#F7){ref-type="fig"}). In keeping with previously published studies ([@B54]) we hypothesized that the mutant PRPF31 protein was aggregating in the nuclei and causing cell death by apoptosis. However, co-immunostaining of cells at each timepoint with caspase-3, a marker of apoptosis, did not confirm this. We consider two alternative possible hypotheses to explain the observation of nuclear abnormalities; that expression of mutant PRPF31 has an effect on centrosomal stability, affecting separation of nuclear material in mitosis, or that expression of mutant PRPF31 causes genome instability. The first hypothesis is consistent with recent findings that PRPF31 localizes to the primary cilium's basal body, which is derived from the centrosome ([@B49]). The second hypothesis is consistent with the recent findings that the splicing machinery plays an important role in DNA damage response sensing, in association with the transcription machinery ([@B43]). This will require further investigation beyond the scope of this project.

![*In vitro* characterization of *PRPF31* c.341T \> A Ile114Asn variant in hTERT-RPE1 cells. **(A)** Immunofluorescence confocal images of RPE1 cells transfected with c-myc-tagged wild-type or mutant PRPF31, showing expression and localization of PRPF31-cmyc over 24, 48, and 72 h. c-myc PRPF31 is evenly distributed throughout the nuclei of cells transfected with WT plasmid at each time point, but is concentrated in the nuclei of a few cells in RPE cells transfected with the mutant plasmid, with some cytoplasmic staining. Scale bars = 10 μm. **(B)** Graphs and statistical significance of proportions of cells with nuclear and cytoplasmic c-myc staining after transfection with WT and 341T \> A mutant PRPF31. ^∗^*p* \< 0.05, *n* = 4. Error bars show standard error of the mean. **(C)** At 72 h, nuclei staining shows many micronuclei (gray arrows) and nuclei with abnormal morphology (blue arrows) in the cells transfected with mutant PRPF31. Scale bars = 10 μm. **(D)** Graphs and statistical significance of proportions of cells with abnormal nuclei morphology and micronuclei. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, *n* = 4.](fgene-10-00248-g006){#F6}

![*In vitro* characterisation of *PRPF31* c.341T \> A Ile114Asn variant in 661W photoreceptor-like cells. **(A)** Immunofluorescence confocal images of 661W photoreceptor-like cells transfected with c-myc-tagged wild-type or mutant PRPF31, showing expression and localization of PRPF31-cmyc over 24, 48, and 72 h. c-myc PRPF31 is evenly distributed throughout the nuclei of cells transfected with WT plasmid at each time point, but is concentrated in the nuclei of a few cells in 661W cells transfected with the mutant plasmid, with some cytoplasmic staining. Scale bars = 20 μm. **(B)** Graphs and statistical significance of proportions of cells with nuclear and cytoplasmic c-myc staining after transfection with WT and 341T \> A mutant PRPF31. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, *n* = 3. Error bars show standard error of the mean. **(C)** At 72 h, nuclear staining shows many micronuclei (gray arrows) and nuclei with abnormal morphology (blue arrows) in the cells transfected with mutant PRPF31. Scale bars = 20 μm. **(D)** Graphs and statistical significance of proportions of cells with abnormal nuclei morphology and micronuclei. ^∗^*p* \< 0.05, ^∗∗∗^*p* \< 0.001, *n* = 3.](fgene-10-00248-g007){#F7}

In order to investigate whether c.341T \> A p.Ile114Asn affected protein stability in a similar way, we transfected HEK293 cells, a human embryonic kidney cell line which is useful for expressing protein at high levels for protein extraction experiments, with plasmids expressing either wild-type PRPF31 or PRPF31 341T \> A, both tagged with c-myc epitope tag. We treated the transfected cells with cycloheximide protein translation inhibitor over a time course of 6 h, and assayed protein concentration over this period via western blotting.

Following our usual method for total protein extraction from cells using 1% NP40 detergent, we had difficulty extracting any mutant protein from the transfected cells ([Figure 8A](#F8){ref-type="fig"}). This was despite the fact that we could observe protein expression in both cell types via immunofluorescent staining with anti-PRPF31 and anti-cmyc antibodies. We proceeded to repeat the experiment using cell fractionation, to selectively extract protein from the nuclear fraction using 0.1% SDS. This yielded a small amount of mutant protein ([Figure 8B](#F8){ref-type="fig"}). Based on our observations, we hypothesized that the mutant protein was in the insoluble nuclear fraction. Once again, we fractionated the cells and lysed the nuclei with 0.1% SDS, but this time we did not remove the insoluble material by centrifugation, instead loading both soluble and insoluble nuclear protein on the gel. This revealed mutant protein, and confirms that the mutant protein is expressed in cells, but is insoluble ([Figure 8C](#F8){ref-type="fig"}). No difference in protein stability was observable in the course of cycloheximide treatment ([Figure 8C](#F8){ref-type="fig"}). Once we had optimized protein extraction from these cells, we were able to confirm our finding from immunofluorescent imaging that both the WT and mutant protein localized to the nucleus, not the cytoplasm ([Figure 8D](#F8){ref-type="fig"}).

![Western blots of protein extracted from HEK293 cells transfected with wild-type or c.341T \> A PRPF31 tagged with c-myc. **(A)** Cells treated with 30 μM cycloheximide (CHX) over 6 h, and soluble protein extracted from the whole cell showed stable levels of wild-type protein expression across the time course, and complete absence of mutant protein in the soluble whole cell fraction. β-actin is cytoplasmic loading control. **(B)** Cells treated with 30 μM cycloheximide (CHX) over 6 h, and soluble protein extracted from the nucleus showed stable levels of wild-type protein expression across the time course, and extremely low levels of mutant protein in the soluble nuclear fraction, except where some insoluble protein was accidentally loaded (4 h). β-actin is cytoplasmic loading control. PCNA is nuclear loading control. **(C)** Cells treated with 30 μM cycloheximide (CHX) over 6 h, and both soluble and insoluble protein extracted nucleus showed similar levels of wild-type and mutant protein expression and stability. PCNA is nuclear loading control marker. **(D)** Fractionation shows that both mutant and wild-type PRPF31 are localized to the nucleus. β-actin is cytoplasmic loading control, PCNA is nuclear loading control.](fgene-10-00248-g008){#F8}

In summary, our findings suggest that c.341T \> A p.Ile114Asn variant in *PRPF31* results in protein insolubility, with downstream effects on nuclear morphology, and is likely the pathogenic cause of RP in this individual. *In silico* structural analysis of this variant complemented existing techniques for predicting pathogenicity of this variant.

Discussion
==========

PRPF31 is a component of the major and minor spliceosome, the huge macromolecular ribonucleoprotein (RNP) complex which catalyzes the splicing of pre-messenger RNAs (pre-mRNAs) to remove introns and produce mature mRNAs. More than 90% of human genes undergo alternative splicing ([@B47]), and splicing is a core function of cells, remarkably well conserved from yeast to man. The spliceosome is composed of at least 43 different proteins, and 5 small nuclear RNAs (snRNAs), U1--U5 ([@B51]).

PRPF31 is essential for the assembly of the U4/U6.U5 tri-snRNP complex ([@B29]), which, when combined with U1 and U2, forms the 'B complex'. After large rearrangements, the activated B complex is able to initiate the first step of splicing. In the absence of PRPF31, U4/U6 di-snRNP accumulates in the splicing-rich Cajal bodies in the nucleus, preventing formation of the tri-snRNP, and subsequently efficient splicing ([@B38]).

PRPF31 performs its function through several important protein domains; the flexible loop, Nop domain, coiled-coil domain and tip. The flexible loop (residues 256--265) protects the exposed C4' atoms of residues 37 and 38 from attack by free radicals, to protect the RNA without directly contacting it ([@B28]). The Nop domain is a conserved RNP-binding domain, with regions for binding protein and RNA. Although the sequence conservation of the Nop domain is relaxed in PRPF31, its specificity for binding U4 or U4atac and 15.5K protein is high ([@B28]). The protein also has several phosphorylation sites, clustered in the C-terminus ([@B28]).

Pathogenic variants in *PRPF31* were discovered as a cause of autosomal dominant RP with incomplete penetrance in 2001 ([@B46]). Since then, more than 100 different variants have been reported in *PRPF31* in Human Gene Mutation Database^[2](#fn02){ref-type="fn"}^, and *PRPF31* has been identified as one of the most common genetic causes of adRP ([@B27]; [@B3]; [@B53]; [@B41]; [@B10]; [@B9]; [@B44]; [@B30]). Most of these pathogenic variants are nonsense, frameshift insertions and deletions and large-scale copy number variants, which are easy to clinically characterize. However, the pathogenicity of missense variants in *PRPF31* is much more difficult to predict, and many missense variants in *PRPF31* remain in variant databases such as ClinVar, under the category of 'unknown clinical significance.' This is made difficult by several factors. Firstly, predictions of pathogenicity based on conservation level of specific residues is unreliable in PRPF31. Whilst PRPF31 is a highly conserved protein, even the most important functional domains in the PRPF31 show relaxed sequence conservation whilst still maintaining high specificity for protein interactions ([@B28]). Indeed, several pathogenic missense variants in PRPF31 are at residues which are not highly conserved, such as Ala194Glu, and Ala291Pro which is predicted to be tolerated by SIFT ([Table 3](#T3){ref-type="table"}). Thus, conservation of 2D protein structure (i.e., amino acid sequence), which is the basis for the tool SIFT, may not be an accurate predictor of pathogenicity of missense variants in this protein. Our study illustrates the importance and utility of using *in silico* 3D spliceosome protein complex analysis ([@B5]) for predicting novel pathogenic missense variants in PRPF31. 3D complex analysis is particularly useful in the case of PRPF31, in which 2D conservation is a poor predictor of pathogenicity, and which has been resolved in complex in high resolution. It is important to note that the spliceosome is a highly dynamic structure, and our 3D structural complex analysis only studies PRPF31 in one specific conformation, in the spliceosome primed for splicing ([@B5]). For truly accurate predictions of pathogenicity, the 3D structure of the spliceosome at different stages of activity will need to be studied, preferably using Molecular dynamic simulation (MDS) with a package such as GROMACS ([@B4]) to provide deepest insights into effects of missense mutations. The publication of more cryo-EM resolved complexes relevant to development of ciliopathies, such as the intraflagellar transport (IFT) complexes ([@B21]) will further enhance our understanding of such conditions, and allow more accurate computational prediction of pathogenicity of variants.

Assessments of pathogenicity of variants in PRPF31 are also limited by the fact that only three missense variants in PRPF31 have been characterized in *in vitro* studies; Ala194Glu and Ala216Pro ([@B11]) and more recently Leu197Pro ([@B7]), meaning that there is little confidence in ascribing pathogenic status to variants outside this region. Earlier studies described these residues as being contained within the Nop domain ([@B11]), leading to conclusions that variants in the Nop domain are more likely to be pathogenic, but recent studies suggest that this is not accurate. Resolution of the crystal structure of PRPF31 has shown that these variants are in alpha helix 6 of the coiled-coil domain, rather than the Nop domain ([@B28]). Published missense variants are found throughout the protein, and our study illustrates that missense changes toward the N-terminal of the protein are also pathogenic.

We suggest that all rare missense variants in PRPF31 should be considered as potentially pathogenic, irrespective of their location within the protein. Constraint metrics, which provide quantitative measures of the extent to which a gene can tolerate change, indicate that *PRPF31* gene as a whole has an extremely low tolerance to missense variants (*Z* = 3.27) ([@B25]). *PRPF31* is particularly intolerant to missense changes even when compared to the other most common causes of adRP; *RPGR*, (*Z* = 1.51) and *Rho* (*Z* = 0.33). Despite the fact that Rho is more tolerant to missense changes, nearly all reported pathogenic changes in Rho are missense changes. This suggests that missense variants in PRPF31 are likely to be pathogenic even in residues with poor conservation, low Grantham score, or low PolyPhen/SIFT scores, if they are observed at low frequency in population variant databases. However, it is important to bear in mind incomplete penetrance associated with PRPF31, so presence of variant alleles in control population databases should not exclude particular variants as a cause of disease.

As well as providing data which can aid interpretation of *PRPF31* genetic findings in patients, our study provides deeper insights into the cell biology associated with pathogenic PRPF31 variants. Consistent with previous studies of Ala194Glu variant PRPF31 ([@B11]), we show that Ile114Asn variant PRPF31 does not prevent translocation of PRPF31 to the nucleus, but reduces the solubility of the protein in the nucleus. We hypothesize that this prevents normal PRPF31 protein function, effectively removing one copy of the protein from cells. This supports previous suggestions that haploinsufficiency is the common disease mechanism in RP11 rather than any dominant negative effects of missense variants ([@B1]; [@B40]; [@B50]). Our novel observation that expression of mutant PRPF31 in cells results in abnormal nuclei supports a growing body of evidence that pre-mRNA splicing factors have multiple roles beyond splicing, including in cilia function and DNA damage sensing. It will be important to investigate this further, as it may offer novel insights into why variants in pre-mRNA splicing factors lead to retinal degeneration.

In summary, we highlight the potential pathogenicity of missense variants in PRPF31, irrespective of their location in the protein. We show the power of a combined approach to variant classification which considers clinical information, *in silico* modeling of 3D protein complex structure and *in vitro* studies for this protein. A combined approach is required to characterize the effect of missense variants in this protein which is both highly conserved, yet has regions of functional importance but surprising relaxation of conservation. We advise caution in disregarding missense variants in PRPF31 as unlikely to be pathogenic, particularly if those conclusions are based upon lack of sequence conservation. We suggest it is more important to study the effect of a missense variant on 3D protein structure rather than 2D amino acid sequence. We provide novel insights into the effect of missense variants in PRPF31 on retinal cell biology; we confirm previous findings that missense variants reduce solubility but find no evidence that leads to apoptosis of cells in the first 72 h of expression, in contrast to previously published data. We observe novel changes in nuclear morphology as a result of PRPF31 mutation which have not been reported previously, and warrant further investigation.

Considerable further work is required to elucidate why haploinsufficiency of PRPF31 causes retinal cells to degenerate, whether specific or global pre-mRNA splicing is affected, and why other tissues outside the retina are not affected by loss of protein.
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###### 

3D cartoon representation of PRPF31, including published missense mutations, in complex with U4 snRNA, 15.5K and PRPF6. **(A)** Cartoon representation of alpha helical structure of PRPF31 (gray) and 15.5K/SNU13 (pink) with U4 snRNA (dark orange backbone), and PRPF6 (blue) with published missense mutations mapped onto the physical structure, with wild-type amino acid structure in green, and mutant amino acid structure overlaid in red. This shows that only Arg408Trp is in interacting proximity with PRPF6. **(B)** An alternative view of the same complex, highlighting that variants in the NOP domain (black arrow) and coiled-coil domain do not appear to interact with PRPF6 in this conformation.
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Click here for additional data file.

###### 

3D cartoon representation of PRPF31, including published missense mutations, in complex with U4 snRNA, 15.5K, PRPF6 and PRPF8. **(A)** Cartoon representation of alpha helical structure of PRPF31 (gray) and 15.5K/SNU13 (pink) with U4 snRNA (dark orange backbone), PRPF6 (blue), and PRPF8 (light orange) with published missense mutations mapped onto the physical structure, with wild-type amino acid structure in green, and mutant amino acid structure overlaid in red. This shows that only Gly261Arg is in interacting proximity with PRPF8. **(B)** An alternative view of the same complex, highlighting that only this Gly261Arg variant (black arrow) appears to interact with PRPF8 in this conformation.
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###### 

*In vitro* characterization of *PRPF31* c.581C \> A Ala194Glu variant in hTERT-RPE1 cells. Immunofluorescence confocal images of RPE1 cells transfected with c-myc-tagged 581C \> A mutant PRPF31, showing expression and localization of PRPF31-cmyc over 24, 48, and 72 h. c-myc PRPF31 is intensely expressed in the nuclei of cells transfected with the mutant plasmid at 24 h, and this becomes restricted to micronuclei and abnormal nuclei over time. A number of micronuclei and abnormal nuclei can be seen at each time point, most noticeably at 72 h (blue and gray arrows). Scale bars = 20 μm.

###### 

Click here for additional data file.

[^1]: Edited by: Jose Maria Carvajal-Gonzalez, Universidad de Extremadura, Spain

[^2]: Reviewed by: Diana M. Horrigan, Brown University, United States; Angel Carlos Roman, Universidad de Extremadura, Spain

[^3]: ^†^Present address: Gabrielle Wheway and Liliya Nazlamova, Human Development and Health, University of Southampton, Southampton, United Kingdom

[^4]: This article was submitted to Genetic Disorders, a section of the journal Frontiers in Genetics
